Winter 2026

Verification and Validation Automation and Test Tools Engineering Co-op

Posted on 9/11/2026

GE Healthcare

GE Healthcare

1-10 employees

Imaging, monitoring, and healthcare IT solutions

No salary listed

No H1B Sponsorship

Madison, WI, USA

Remote

Relocation is required; relocation assistance is provided.

Bachelor's

Category
QA & Testing (1)
Required Skills
Python
Usability Testing/Engineering
Software Testing
Quality Assurance (QA)
C#
C/C++

Get referred to GE Healthcare

See people who can refer or advise you

Requirements
  • Demonstrate computer science or engineering skills in C++, Python, or C#.
  • Demonstrate analytical ability and technical competency in Computer Science, Biomedical Engineering, or Computer Engineering areas.
  • Communicate technical problems clearly and simply.
  • Work independently and in teams.
  • Be able to work for a minimum of 30 weeks.
  • Be a full-time student pursuing a degree in Mechanical Engineering, Electrical Engineering, Computer Engineering, Computer Science, or Biomedical Engineering with an emphasis in Mechanical, Electrical, or Computer Engineering.
  • Be willing to relocate.
  • Have legal authorization to work in the United States.
Responsibilities
  • Develop and maintain test tools and automation frameworks used to verify and stress the functionality of Life Support devices, including Infant Care and Anesthesia Systems.
  • Code and execute Verification and Validation procedures using structured and creative test approaches.
  • Stress the design quality of anesthesia and respiratory care systems to identify defects before product manufacturing.
  • Interact with development engineers to understand and analytically stress the functionality, performance, and usability of system features.
  • Work hands-on with assembled prototype systems to identify defects in product designs.
Desired Qualifications
  • Have a cumulative overall GPA of 3.0 or better on a 4.0 scale.
  • Have prior internship, co-op, or research experience in computer science, engineering, or design research.
  • Demonstrate an analytic approach to problem solving.
  • Demonstrate adaptability to difficult situations.
  • Have leadership skills and community involvement.

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Photonova Spectra won CE Mark on August 31, 2026, opening Europe sales.
  • Q2 2026 orders rose 11.1%, with 1.15x book-to-bill and record backlog.
  • Vivid cardiovascular ultrasound and ABUS breast screening launches broaden 2026 revenue opportunities.

What critics are saying

  • Patient Care Solutions revenue fell 13.5% in Q2 2026; management is reviewing a sale.
  • Jay Saccaro left in August 2026; William Grogan starts September 14, 2026.
  • If PCS recovery slips into 2027, GE HealthCare becomes a slower-growth imaging vendor.

What makes GE Healthcare unique

  • Photonova Spectra’s Deep Silicon CT differentiates GE HealthCare with photon-counting imaging.
  • GE HealthCare spans imaging, pharma diagnostics, ultrasound, and monitoring across hospital workflows.
  • The July 2026 backlog of $23.9 billion reflects sticky installed-base demand and services.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

Yahoo Finance
Sep 1st, 2026
GE HealthCare secures CE mark for Photonova Spectra photon-counting CT system

GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.

Yahoo Finance
Aug 31st, 2026
Vertex Pharmaceuticals shows promise while GE HealthCare and Wells Fargo face challenges

Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.

Associated Press
Aug 28th, 2026
GE HealthCare launches three new Vivid cardiovascular ultrasound systems for diverse care settings

GE HealthCare has introduced three new cardiovascular ultrasound systems to its Vivid portfolio: Vivid Explorer 1, Vivid Advanced 1, and Vivid Focus 1. The systems were unveiled at the European Society of Cardiology Congress 2026 in Munich, Germany. Each system targets different clinical settings whilst sharing a common technology foundation with the ultra-premium Vivid Pioneer. Vivid Explorer is designed for high-volume echo labs, Vivid Advanced for mid-size hospitals and cardiology practices, and Vivid Focus for everyday cardiac imaging. All three systems use cSound imaging technology and include AI-enabled automation tools to streamline echo workflows. The systems have received CE Mark approval but are awaiting US FDA 510(k) clearance and are not yet available for sale in the United States.

Yahoo Finance
Aug 3rd, 2026
GE HealthCare launches Invenia ABUS Prime and StreamVue for breast cancer screening

GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.

Yahoo Finance
Jul 29th, 2026
GE HealthCare Q2: Orders up 11%, backlog hits record $23.9B amid Patient Care struggles

GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.